by Raynovich Rod | Jun 10, 2024 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Healthcare stocks
Update-4…6/29….I’m back but I did not miss much in biotech trades, but a lot of “3 day wonders'” you know stocks that get momentum then quickly fade. The XBI is still holding above the $90 support level with a range of $89.13 to $94.88...
by Raynovich Rod | May 28, 2024 | 2023-24 Life Science Portfolios, Life Science ETF's and Mutual Funds
Update: 6/7/24.,,Our model still looks good for experienced traders.Today for example GERON (GERN) soared 19% with approval of RYTELO for MDS associated anemia. We will summarize news from winning stocks over the weekend. XBI was weak today down about 1% to $91...
by Raynovich Rod | May 13, 2024 | 2023-24 Life Science Portfolios
Update-4 5/23/24…XBI down 3% to $89 handle, rates up =risk off, But S&P hold 5200. NVDA rules nothing else in broad sell-off. Update-3 5/22…XBI is holding the $92 level and several SMID stocks show gains:ADPT, CRNX,CRSP, PACB, TXG. NTRA near 52 wet...
by Raynovich Rod | May 12, 2024 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio
Healthcare and Biotech Investing 101: What you need to know. What is your current allocation for healthcare stocks? Large cap stocks that pay dividends are the best positioned for growth plus value. Start with an ETF plus one Fund. If you have been reading our...
by Raynovich Rod | May 2, 2024 | 2023-24 Life Science Portfolios, 2024 Rayno Tools and Diagnostics Portfolio
Update-5 SMIDS are running today. Added NVAX to list. ADPT RXRX XBI are movers. UPDATE-4…AT close…XBI tried to rally back to $90 but closed at $88+. XBI drives SMID biotechs and as you can see it’s a red screen day if you are tracking our spec...
by Raynovich Rod | Apr 29, 2024 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio
MAY 1..3:00P EDT…XBI up over 5 %, Spec biotech rally! Details later. April 30 …Sell off at close -FED jitters plus yieldsup not a good combo. Labor costs rise,US consumer sentiment drops ,worst month since 9/22. NAZ and Russell down over 2%, S&P down...
by Raynovich Rod | Apr 24, 2024 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-2 4/26..ABBVIe (ABV) beats on sales and earnings but Humira revenue concerns linger stock down 4+%. SMID caps up: CRMD,CYRX, GERN,SUPN, TXG etc….XBI up 1.5% after dipping to $81 . Update-1 4/25…MRK up over 3% on confirmed guidance Revs at...
by Raynovich Rod | Apr 15, 2024 | 2023-24 Life Science Portfolios
Update-2…4/18…Sellers may be going away but buyers are still in hiding. XLV flat at $138.49, IBB down 0.99%, XBI down 1.385 at $83.48.UNH continues recovery up 2.96% at $493. Choppy tape with a reddish screen. Noted weakness in chip stocks with AMAT down...
by Raynovich Rod | Mar 31, 2024 | 2023-24 Life Science Portfolios, Biopharmaceuticals
Update-3 4/5/24 Steady gains with a lot of green. Small cap life science 2+% gains: CRMD, CRNX, CYTK,GERN, NTRA,RXRX,TWST. XBI holding at $90 level. Update-2 4/4/24 Stocks reversed after some early strength as small caps and momentum trades took a hit. Selling picked...
by Raynovich Rod | Mar 25, 2024 | 2023-24 Life Science Portfolios, Biopharmaceuticals
Update-1 MRK up 5% to $131.81 on FDA approval of PAH (Pulmonary Arterial Hypertension) Drug. ABBV and LLY get small gains SUPN up 3.88%. Nice pick-up in momentum from our SMID trading list: ABOS, CPRX, CRMD, CYRX, PACB, ROIV,, VCEL, VCYT, etc, XBI up 2.38%. XLV...
